Previous 10 | Next 10 |
home / stock / lly / lly articles
Some 42% of adults in the United States are affected by obesity, according to the U.S. CDC. At a global level, a new study released by the journal ...
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage company focused on developing novel therapeutics for metabolic and endocrine disorders, has be...
Novo Nordisk A/S (NYSE:NVO) says that despite earlier warnings from the Danish Medicines Agency about potential shortages of Wegovy, it does n...
The first-quarter results of the healthcare sector have been unimpressive, with earnings of 78% of the sector participants that have reported so fa...
Researchers at Alphabet Inc’s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google DeepMind have developed AlphaFold 3, an new artificial intelligence (...
Legendary hedge fund manager Stanley Druckenmiller is known for making the right bets at the right time. He came to fame In the early ’90s af...
Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committ...
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 15 years by 10.37% on an annualized basis producing an average annual return ...
Online pharmacies and slimming clinics in Britain are reducing prices for Novo Nordisk A/S’s (NYSE:NVO) Wegovy and&n...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...